Author + information
- Received March 31, 1997
- Revision received August 8, 1997
- Accepted October 23, 1997
- Published online February 1, 1998.
- Nowamagbe A. Omoigui, MD, MPH, FACCA,* (, )
- Mitchell J. Silver, DOB,
- Lisa A. Rybicki, MSB,
- Monique RosenthalB,
- Lisa G. Berdan, PA-C, MHSC,
- Karen Pieper, MSC,
- Samuel V. King, MDA,
- Robert M. Califf, MD, FACCC,
- Eric J. Topol, MD, FACCB,
- for the CAVEAT I and II Investigators1
- ↵*Dr. Nowamagbe A. Omoigui, Division of Cardiovascular Diseases, University of South Carolina School of Medicine, Two Medical Park, Suite 501, Columbia, South Carolina 29203.
Objectives. We sought to determine whether the results of the first Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) influenced subsequent practice patterns among the investigators.
Background. CAVEAT-I demonstrated that directional coronary atherectomy (DCA) resulted in higher rates of early complications at a higher cost and with no clinical benefit. We sought to determine whether these results influenced subsequent use of procedures among CAVEAT-I investigators.
Methods. We compared the results of a week-long registry of all coronary interventions performed at 35 CAVEAT-I sites in 1994 with those of a similar registry obtained in 1992 before the trial, the results of which were published in 1993. For control purposes, the use of procedures was studied at 24 additional sites to provide insight into practice at hospitals not participating in the trial. A total of 1,465 interventions were analyzed.
Results. Ninety-four percent of CAVEAT-I sites responded. Utilization rates differed between CAVEAT-I and CAVEAT-I follow-up (p < 0.001). Balloon angioplasty decreased from 83.8% to 68.5%, DCA increased slightly from 10.7% to 14.1%, and the use of other devices increased from 5.4% to 17.5%. Stand-alone balloon use was more prevalent at nonparticipating control sites than at sites that took part in CAVEAT-I (p < 0.001).
Conclusions. Paradoxically, despite the negative findings of CAVEAT-I, there was a noteworthy trend toward an increase in the use of DCA and other devices at CAVEAT-I sites. Our findings suggest that among investigators in the trial, there may have been a lack of influence of trial data on clinical practice patterns 1 year after publication of the results. Ethics of protocol: Both CAVEAT I and II were approved by the Institutional Review Board at each study site.
- Received March 31, 1997.
- Revision received August 8, 1997.
- Accepted October 23, 1997.
- The American College of Cardiology